How does T-cell acute lymphoblastic leukaemia go to the brain?
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Advance testing efficacy of albendazole in childhood acute myeloid leukaemia
Investigating the preclinical efficacy of albendazole in paediatric acute myeloid leukaemia
Understanding a potentially new therapeutic target in incurable childhood acute lymphoblastic leukaemia
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
Optimising therapy in newly diagnosed metastatic Ewing sarcoma
Optimising tyrosine kinase inhibitor therapy in newly diagnosed metastatic Ewing sarcoma
New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer
Do errors in the production of antibody genes cause mutations that lead to leukaemias with poor survival rates?
The Role of Cut-and-Run, an Aberrant V(D)J Recombination Reaction, in the Development of Acute Lymphoblastic Leukaemias with Poor Prognosis
High-specificity killing of brain tumour cells using the Zika virus
Towards a new therapy against childhood brain cancer: How does the Zika virus kill aggressive brain tumour cells?
Re-purposing diabetes medication to treat Ewing's sarcoma
Investigating repurposed drugs to decrease the progression of Ewing’s sarcoma
Evaluating the use of novel treatments in combination with current maintenance therapies for the on-going treatment of high-risk neuroblastomas
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study